G4S plc
14.1.2021 16:47:21 CET | Globenewswire | Press release
14 January 2021
G4S PLC
NOTIFICATION OF MAJOR SHAREHOLDING
The company was notified on 14 January 2021 by Skandinaviska Enskilda Banken AB (publ), that following an acquisition of voting rights attached to shares they hold 5.14% of the company's total voting rights.
Celine Barroche
Company Secretary
For further enquiries, please contact:
| Helen Parris |
Director of Investor Relations |
+44 (0) 207 9633189 |
| Media enquiries | ||
| Sophie McMillan | Head of media | +44 (0) 759 5523483 |
| Press office | +44 (0) 207 9633333 |
Notes to Editors:
G4S is the world’s leading global, integrated security company, specialising in the provision of security services and solutions to customers. Our mission is to create material, sustainable value for our customers and shareholders by being the supply partner of choice in all our markets.
G4S is quoted on the London Stock Exchange and has a secondary stock exchange listing in Copenhagen. After taking account of the businesses being sold in the year, G4S is active in around 85 countries and has around 533,000 employees. For more information on G4S, visit www.g4s.com
.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
Orion Oyj18.9.2026 18:00:00 CEST | Press release
Orion Corporation: Acquisition of own shares during week 38, 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
